Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249260 | 1.00 | MDM2 (0.58) | MDM2ACEPTPN1ITGB3ITGA2B | |
| SCHEMBL371161 | 1.00 | MDM2 (0.58) | MDM2ACEPTPN1ITGB3ITGA2B | |
| SCHEMBL29401511 | 0.96 | MDM2 (0.62) | MDM2ACEPTPN1ITGB3ITGA2B | |
| SCHEMBL2307978 | 0.96 | MDM2 (0.62) | MDM2ACEPTPN1ITGB3ITGA2B | |
| SCHEMBL3728072 | 0.96 | MDM2 (0.62) | MDM2ACEPTPN1ITGB3ITGA2B | |
| SCHEMBL14039181 | 0.96 | MDM2 (0.62) | MDM2ACEPTPN1ITGB3ITGA2B | |
| SCHEMBL29445607 | 0.96 | MDM2 (0.62) | MDM2ACEPTPN1ITGB3ITGA2B | |
| SCHEMBL31370376 | 0.94 | MDM2 (0.64) | MDM2ACEPTPN1ITGB3ITGA2B | |
| SCHEMBL21639290 | 0.91 | MDM2 (0.52) | MDM2ACEPTPN1ITGB3ITGA2B | |
| SCHEMBL21639288 | 0.91 | MDM2 (0.52) | MDM2ACEPTPN1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | disclosed |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4677087-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | Glaukos Corporation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | UNIV CALIFORNIA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | ENLAZA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | CHEN LI (US) | 2004-10-21 | — | — | US | disclosed |
| US-6806365-B2 | ACTIVITY AS INHIBITORS OF BINDING BETWEEN VCAM-1 AND CELLS EXPRESSING VLA-4. SUCH COMPOUNDS ARE USEFUL FOR TREATING DISEASES WHOSE SYMPTOMS AND/OR DAMAGE ARE RELATED TO THE BINDING OF VCAM-1 TO CELLS EXPRESSING VLA-4. | HOFFMANN-LA ROCHER INC. | 2004-10-19 | — | — | US | disclosed |
| EP-1005446-B1 | N-AROYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-02-25 | — | — | EP | disclosed |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | CHEN LI (US) | 2003-06-12 | — | — | US | disclosed |
| US-6455550-B1 | INHIBITORS OF BINDING BETWEEN VASCULAR CELL ADHESION MOLECULES AND CELLS EXPRESSING VLA-4 INTEGRIN; ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-09-24 | — | — | US | disclosed |
| US-6359144-B1 | BIOSYNTHESIS; SCREENING | LION BIOSCIENCE AG (DE) | 2002-03-19 | — | — | US | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| US-6001810-A | ADDING STO A BIOLOGICAL SOLUTION CONTAINING RETROVIRAL PROTEASE AN INHIBITORY AMOUNT OF SHORT PEPTIDES OF SPECIFIEDAMINO ACID SEQUENCES | ELI LILLY AND COMPANY (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
| EP-0431784-A2 | Methods for treating retroviral infection | ELI LILLY AND COMPANY (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | P2RX7, NLRP3, PYCARD | MDM2 4747/4885ACE 3545/4885PTPN1 388/4885 |
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | MDM2 2671/4885ACE 1258/4885PTPN1 4658/4885 |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | VCAM1, ICAM1, SELL | MDM2 4833/4885ACE 1889/4885PTPN1 2741/4885 |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | PBK, CD4, ICOS | MDM2 3089/4885ACE 2924/4885PTPN1 1197/4885 |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | FCGR3B, FCGR2A, CD22 | MDM2 2289/4885ACE 2929/4885PTPN1 2363/4885 |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | VCAM1, ICAM1, CD59 | MDM2 4414/4885ACE 1595/4885PTPN1 2232/4885 |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | POLB, POLM, POLRMT | MDM2 3883/4885ACE 565/4885PTPN1 4678/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | MDM2 3725/4885ACE 663/4885PTPN1 4318/4885 |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | FCGR2A, FCGR3B, CD74 | MDM2 3930/4885ACE 2014/4885PTPN1 737/4885 |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | ALOX15, ALOX12, PTGES | MDM2 4708/4885ACE 3413/4885PTPN1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.